Hybrid treatment of multilevel revascularization in patients with peripheral arterial disease - a multi-centre study in Korea

• Published in: VASA Vol. 47; no. 3; p. 235
• Main Authors: Lee, Soon Cheon, Joh, Jin Hyun, Chang, Jeong-Hwan, Kim, Hyung-Kee, Kim, Jang Yong, Park, KiHyuk, Hong, Ki Chun, Byun, Seung Jae, Lee, Tae Seung, Jung, Hyuk Jae, Lee, Sang Su
• Format: Journal Article
• Language: English
• Published: Switzerland 01.04.2018
• Subjects: Hybrid treatment; peripheral arterial disease; multilevel revascularization
• ISSN: 0301-1526
• DOI: 10.1024/0301-1526/a000694

Endovascular treatment is an alternative first-line management for peripheral artery disease (PAD). Hybrid treatment (HT) is defined as a combined treatment for patients with PAD using endovascular and open surgery, simultaneously performed in an operating room. The results of HT are reportedly good for multilevel revascularization (MR) in patients with chronic limb ischaemia, and even in older high-risk patients. The goal of this study was to examine the clinical and haemodynamic outcomes of HT in patients who need MR. Nine university hospitals in Korea participated in this multicentre study. A total of 134 patients with multilevel PAD underwent HT and MR. Patients were enrolled from July 2014 to June 2015 and were followed for 18 months. The mean age of the patients was 68.8 ± 9.93 years and 88.1 % were men. Patients with Rutherford category 2 to 3 and 4 to 6 comprised 59.0 % and 42.0 % of the group, respectively. The technical success rate was 100 %. The primary patency rates at 12 and 18 months were 77.6 % and 63.9 %, respectively. The primary-assisted patency rates at 12 and 18 months were both 90.0 %. The pre-operative mean ankle brachial index (0.43 ± 0.23) increased to 0.87 ± 0.23 at six months post-operatively (t-test, p < 0.05). The amputation free survival rate was 97.1 %. Although outcomes of multilevel PAD are reportedly poor when endovascular treatment alone is used, we have shown that HT is a feasible alternative modality for patients with multilevel PAD, with satisfactory amputation-free survival and freedom from re-intervention rates.